Navigation Links
MacroGenics Enters Global Research Collaboration and License Agreement with Pfizer
Date:10/26/2010

ground

MacroGenics' DART technology enables the generation of highly stable antibody-based therapeutic molecules that can simultaneously target two different antigens. DART therapeutics can accommodate virtually any variable region sequence in a "plug-and-play" fashion, are potent, and have very favorable manufacturing properties. To date, the company has engineered over 65 different DART proteins and has completed multiple in vitro and in vivo proof-of-concept studies in a variety of disease models. The company has been able to produce DART proteins in both bacterial and mammalian expression systems. DARTs also have been engineered with an Fc domain, which confers them with additional properties, such as Fc receptor binding and extended half-life. This functionality can be further expanded with the inclusion of MacroGenics' proprietary Fc domain portfolio. MacroGenics has established and continues to expand a significant patent estate around its DART technology.

About MacroGenics

MacroGenics is a private, venture-backed biotechnology company that focuses on the discovery, development and delivery to patients of novel biologics for autoimmune disorders, cancer and infectious diseases. Since its founding in 2000, the company has built a fully-integrated set of capabilities in antibody-based product development. The company has generated a proprietary pipeline of innovative product candidates by leveraging its three core technology platforms. These proprietary platforms include: (1) cancer stem-like cells; (2) DART technology, which allows the company to incorporate multiple specificities within a single molecule; and (3) Fc optimization, which enhances antibody-dependent effector functions. The company's lead program, teplizumab, is an anti-CD3 antibody. Teplizumab is being investigated in Phase 3 trials for the treatment of autoimmune diseases in collaboration with Eli Lilly and Company. For more information about MacroGenics, please
'/>"/>

SOURCE MacroGenics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MacroGenics Receives NIH Grant Funding of $9.8M for Three Projects; Funding Further Advances DART Platform and Infectious Disease Portfolio
2. MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus
3. Paulo F. Costa Joins MacroGenics Board of Directors
4. MacroGenics Appoints New Vice President of Business Development
5. MacroGenics Raises $25M in Series D-2 Financing
6. Shrink Nanotechnologies Enters Into Agreement to Produce High Content Screening Software Called Stemage for its StemDisc Stem Cell Culturing Products
7. HumanTouch Expands Services to the Centers for Disease Control and Prevention as a Prime Contract Holder as Part of $1.0 Billion Contract
8. NSF renews Centers for Nanotechnology in Society
9. Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement
10. ReGear Life Sciences Partners with Life Care Centers of America
11. Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Research and Markets  has announced ... for Flow Cytometry in IVD Applications" report ... http://photos.prnewswire.com/prnh/20130307/600769 Flow cytometers are powerful ... component of advanced IVD labs in developed nations. ... but their newer clinical applications included the commercialization ...
(Date:8/1/2014)... Frederick, MD (PRWEB) August 01, 2014 ... and RFID Solutions provider, today officially announces the ... the prestigious Boji Science Park, Baoshan District in ... RURO Shanghai is under the management of Mr. ... International. , In the past three years, RURO’s ...
(Date:8/1/2014)... Aug. 1. 2014 As one of the ... AACC Annual Meeting & Clinical Lab Expo is the ... care are introduced to the healthcare world. This year, ... 650 exhibitors will include the latest diagnostic technology in ... in smartphones and biosensors have enabled the development of ...
(Date:8/1/2014)... Aug. 1, 2014 AACC, a global scientific ... laboratory medicine, unveiled an updated brand identity today that ... to the changing healthcare environment and continue to do ... so patients get the care they need. ... membership play an essential role in saving lives and ...
Breaking Biology Technology:The World Market for Flow Cytometry in IVD Applications 2RURO Opens Office in Shanghai, China 2Lab-on-a-Chip Technology to Be Featured at 2014 AACC Annual Meeting & Clinical Lab Expo 2Lab-on-a-Chip Technology to Be Featured at 2014 AACC Annual Meeting & Clinical Lab Expo 3AACC Debuts Refreshed Brand Identity 2
... long-awaited speaking faculty for the September Pharma ChemOutsourcing ... conference website reports Mark Alexay, President of Apaporis ... comprised of 100 speakers from pharmaceutical companies and ... the pipeline. The speaker list may be viewed ...
... Christine Lawless, MD, has accepted the position as ... continuing medical education (CME), beginning March 2, 2009. Recognized ... medicine cardiology, Dr. Lawless recently completed her clinical tenure ... where she was Associate Professor of Internal Medicine and ...
... Endpoints,NEW YORK, March 10 Intra-Cellular Therapies, Inc. today ... trial in patients with Sleep Maintenance Insomnia (SMI). ... wave sleep and decreased the duration of wake after ... prespecified primary and key secondary endpoints of the trial. ...
Cached Biology Technology:Pharma ChemOutsourcing Unveils 100 Pharma & Biotech Speaker Faculty for 2009 Conference September 14-16 in Long Branch, NJ 2Former President of Sports Cardiology Consultants, LLC Christine Lawless, MD, MBA, ABCL, FACC, FACSM, Named Medical Director of CME Enterprise 2Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 2Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 3Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 4Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 5Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 6Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 7
(Date:8/1/2014)... 1, 2014Lesbian, gay, bisexual, and transgender individuals who want ... as some of their heterosexual and cisgendered peers, such ... additional physiological and legal challenges to become parents. ... assisted reproduction options is presented in the article " ... published in LGBT Health , a ...
(Date:8/1/2014)... group of marine mammals have officially named a ... Sousa sahulensis , according to the Wildlife ... study describing the newly named species is the ... all available historical records, physical descriptions, and genetic ... cetaceans ranging from the coast of West Africa ...
(Date:8/1/2014)... tricky enough. Knowing what causes them at the molecular ... Iowa researchers have created the most detailed map to ... associated with blinding diseases, such as age-related macular degeneration. ... the choroid, which supplies blood and oxygen to the ... in the abundance of proteins in different areas of ...
Breaking Biology News(10 mins):Advances in assisted reproduction create more options & new legal issues for LGBT couples 2Scientists name new species of cetacean: The Australian humpback dolphin 2Scientists name new species of cetacean: The Australian humpback dolphin 3A map for eye disease 2
... A new technique for transplanting the ovaries of women ... cancer treatment was outlined to the 25th annual conference ... today (Monday 29 June). Dr. Pascal Piver, ... Limoges, France, described a new, two-step method of ovarian ...
... Shingu City, Japan--Deepsea Drilling Vessel CHIKYU has resumed IODP ... the Kii Peninsula of Japan. The scientific drilling expedition,s ... meters. Following sea floor surveys, the crew began fitting ... an upper section of the first borehole to be ...
... June 2009 Elsevier, the leading publisher of scientific, ... the highlights of its journal impact factor performance in ... factors (IF) increase from 2007 to 2008. According to ... journals took the #1 position in 51 categories (of ...
Cached Biology News:Ovarian transplantation: First baby is born after a new technique 2First riser-drilling research operations undertaken 2Elsevier announces 2008 journal impact factor highlights 2Elsevier announces 2008 journal impact factor highlights 3
... long electrophoresis hood is a ... systems. Placed on the transilluminator, ... place and provides a darkroom ... the lab bench. This 15.2 ...
... derived from frozen embedded tissue blocks, which ... to ensure the highest quality. Tissues of ... block, sectioned at a thickness of 7 ... are large (3-5 mm in diameter) in ...
... are derived from frozen embedded tissue blocks, ... procedures to ensure the highest quality. Tissues ... one block, sectioned at a thickness of ... are large (3-5mm in diameter) in comparison ...
... microarrays are derived from Paraffin embedded tissue ... control procedures to ensure the highest quality. ... in one block, sectioned at a thickness ... slides. Sections are large (3-5mm in diameter) ...
Biology Products: